Month: December 2016

December 22, 2016
Emicizumab meets study endpoint

22 December 2016 Prophylaxis with emicizumab reduced the number of bleeds over time compared with no prophylaxis in the HAVEN 1 study, which recruited people aged >12 years with haemophilia A and inhibitors. Manufacturer Roche said the phase III study had also met its secondary endpoints, including a statistically significant reduction in the number of …

Read article